Stock Trading Canary← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Polymeropoulos Mihael Hristos
Chief Executive Officer | President
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001355537
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 0
- Purchases · 24M
- 10
- Average purchase
- $50.5K
- Median purchase
- $47.6K
- Gross purchase value
- $504.8K
Companies: Vanda Pharmaceuticals Inc.
10 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2025-08-08 | Vanda Pharmaceuticals Inc. | VNDA | Chief Executive Officer | President | $41.5K | Open filing |
| 2025-05-21 | Vanda Pharmaceuticals Inc. | VNDA | Chief Executive Officer | President | $44.0K | Open filing |
| 2025-05-19 | Vanda Pharmaceuticals Inc. | VNDA | Chief Executive Officer | President | $84.4K | Open filing |
| 2025-03-06 | Vanda Pharmaceuticals Inc. | VNDA | Chief Executive Officer | President | $50.1K | Open filing |
| 2025-03-05 | Vanda Pharmaceuticals Inc. | VNDA | Chief Executive Officer | President | $50.2K | Open filing |
| 2025-03-04 | Vanda Pharmaceuticals Inc. | VNDA | Chief Executive Officer | President | $47.1K | Open filing |
| 2025-02-28 | Vanda Pharmaceuticals Inc. | VNDA | Chief Executive Officer | President | $47.6K | Open filing |
| 2025-02-27 | Vanda Pharmaceuticals Inc. | VNDA | Chief Executive Officer | President | $47.6K | Open filing |
| 2025-02-26 | Vanda Pharmaceuticals Inc. | VNDA | Chief Executive Officer | President | $47.6K | Open filing |
| 2025-02-25 | Vanda Pharmaceuticals Inc. | VNDA | Chief Executive Officer | President | $44.6K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 0/9
- Large purchase ≥ $100k
- 0/10
- Cluster buying · 15D
- 7/10
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.